FSSAI is actively enforcing a crackdown on "100%" and therapeutic claims on food products, and Om Sai Healthcare has been named among the non-compliant companies, specifically for its Vedaflexa Capsules.1211 This represents a preventable compliance failure that exposes the company to regulatory penalties and reputational damage, requiring immediate public acknowledgment and corrective action.113 We recommend a rebuild strategy: publicly confirm the issue, detail the corrective steps already taken (website revisions), and commit to full compliance across all materials, aligning with the sector playbook for speed and traceability.13
THREATEscalated regulatory penalties, including fines, if corrective action is perceived as slow or insufficient.211
THREATLoss of consumer trust and brand credibility, leading to decreased sales.18
THREATNegative media narrative framing the company as a laggard compared to peers who have already complied.351011
OPPORTUNITYDemonstrating proactive compliance and transparency can position the brand as responsible and trustworthy.13
Best response strategy
REBUILD The verified facts show Om Sai Healthcare has already taken initial corrective action by revising website content, which establishes a factual basis for a responsible, forward-looking statement.13 The FSSAI's focus is on misleading marketing language, not product safety, allowing the response to center on compliance and transparency without raising safety concerns.8 Other major brands like Amway and Emami have publicly confirmed their compliance actions, setting an industry standard Om Sai Healthcare must meet to avoid being framed as non-cooperative.3510
Who is watching, and what each expects from the response:
regulatorEnforcing labeling regulations and ensuring widespread industry compliance.28
customersBeing misled by marketing claims and the integrity of the brand.18
mediaThe broader regulatory crackdown story and which companies are complying.2311
investorsPotential financial penalties, operational disruption, and long-term brand damage.113
partnersAssociation with a non-compliant brand and potential supply chain or distribution disruptions.113
Suggested response plan
T+0-4h
Phase 1 — Contain & Verify
Outcome: Internal alignment on the facts, a frozen public communications line, and a verified list of all non-compliant claims across all channels (web, packaging, ads).113
legal
Instruct the legal and compliance team to immediately audit all product labels, packaging, website copy, and advertisements for any "100%", "therapeutic", or "medicinal" claims, cross-referencing against the FSSAI advisory.1213
Freeze all outgoing marketing and social media posts pending review.
Compile a complete inventory of non-compliant claims with their locations (SKU, URL, ad campaign).
Brief the executive team on the full scope of required changes.
Done when: Audit report delivered to the executive team with a complete list of non-compliant claims and recommended corrective actions.
T+4-12h
Phase 2 — Respond & Reassure
Outcome: A public statement acknowledging the issue and corrective action is live, pre-empting further negative coverage and demonstrating cooperation to the regulator.113
comms
Publish the approved statement on the company website's news section and distribute it as a press release to key business and regulatory media outlets.
Post the statement as a news article on the company website.
Distribute the press release via wire service and direct outreach to reporters covering the FSSAI crackdown.
Prepare a brief internal FAQ for employees to ensure a consistent message.
Done when: Statement is live on the corporate website and press release distribution is confirmed.
“Om Sai Healthcare is committed to full compliance with all FSSAI regulations. We have taken immediate action to review and revise our marketing materials, including for Vedaflexa Capsules, to ensure they align with the latest advisory on product claims.113 Our website content has been updated, and we are reviewing all packaging and promotional materials.13 We support FSSAI's efforts to ensure transparent and accurate information for consumers and are working diligently to complete all necessary updates.8” website statementpress release
T+1-3 days
Phase 3 — Manage & Correct
Outcome: All identified non-compliant claims are removed or corrected across digital and physical channels, with a timeline communicated internally for packaging rollouts.13
operations
Execute the corrective action plan from the audit: update all website listings, issue takedown notices for non-compliant digital ads, and finalize a production schedule for revised packaging.613
Implement all website and digital marketing corrections.
Work with packaging suppliers to finalize new artwork and establish a phased production schedule, mirroring the approach taken by peer companies.
Develop a customer care script for any inquiries, focusing on the company's commitment to compliance.
Done when: Digital corrections are complete and a packaging rollout schedule is approved and shared with the leadership team.
Evidence sources (7)
Everything this briefing cites — includes official statements & reference pages that are not press mentions.
Your crisis desk is ready — claim it to respond. Claiming is free — your response strategy & plan become collaborative, and you get the option to display your response & status updates on this page.
One short, factual update when this story develops — nothing else, from over:heard.
Email updates
By subscribing you consent to receive email updates about this story. Double opt-in: nothing is sent until you confirm from your inbox. Unsubscribe anytime — one click in every email.
Push notifications
No email needed — alerts appear on this device.
Not omsaihealthcare.in? See what over:heard would flag for your brand.
Start free →
Independent media-monitoring briefing compiled by over:heard radar from public coverage. Assessments are decision support —
not statements by, or affiliation with, the brands mentioned. · Powered by over:heard by wise:able
